Profile data is unavailable for this security.
About the company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
- Revenue in USD (TTM)47.49bn
- Net income in USD16.39bn
- Incorporated1931
- Employees77.41k
- LocationNovo Nordisk A/SNovo Alle 1BAGSVAERD 2880DenmarkDNK
- Phone+45 44448888
- Fax+45 44436633
- Websitehttps://www.novonordisk.com/
Mergers & acquisitions
| Acquired company | NOVO B:CPH since announced | Transaction value |
|---|---|---|
| Novavax Inc-Manufacturing Facility | -43.89% | 200.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | 11.10bn | -988.90m | 120.40bn | 6.10k | -- | 7.30 | -- | 10.85 | -3.88 | -3.88 | 42.86 | 64.20 | 0.4744 | 1.43 | 6.17 | 1,819,623.00 | -4.23 | 14.06 | -5.04 | 16.67 | 86.03 | 87.35 | -8.91 | 26.28 | 2.29 | -- | 0.0067 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Gilead Sciences Inc | 28.74bn | 5.97bn | 136.38bn | 17.60k | 23.19 | 7.12 | 15.61 | 4.75 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 62.46bn | 7.87bn | 145.83bn | 81.00k | 18.61 | 1.61 | 9.86 | 2.33 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 34.13bn | 5.93bn | 158.77bn | 28.00k | 26.95 | 25.58 | 13.76 | 4.65 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Merck & Co Inc | 63.92bn | 17.43bn | 209.32bn | 75.00k | 12.13 | 4.34 | 9.47 | 3.27 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| Novo Nordisk A/S (ADR) | 47.49bn | 16.39bn | 233.38bn | 77.41k | 18.74 | -- | 12.52 | 4.91 | 3.68 | 3.68 | 10.66 | -- | 0.7693 | 1.24 | 4.79 | 622,440.10 | 26.55 | 27.72 | 54.15 | 55.74 | 84.33 | 84.25 | 34.51 | 34.12 | 0.5571 | 47.34 | 0.4615 | 50.11 | 25.03 | 18.94 | 20.68 | 20.99 | 35.50 | -1.86 |
| AbbVie Inc | 57.37bn | 4.16bn | 339.94bn | 55.00k | 82.06 | 239.38 | 26.95 | 5.93 | 2.35 | 2.35 | 32.39 | 0.804 | 0.4025 | 3.83 | 4.70 | 1,043,036.00 | 2.95 | 5.44 | 4.06 | 7.09 | 70.69 | 68.89 | 7.33 | 13.73 | 0.6359 | 7.80 | 0.9795 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 7.69 |
| Holder | Shares | % Held |
|---|---|---|
| Jennison Associates LLCas of 31 Mar 2025 | 18.82m | 0.56% |
| Loomis, Sayles & Co. LPas of 31 Mar 2025 | 12.39m | 0.37% |
| Fisher Asset Management LLCas of 31 Mar 2025 | 11.87m | 0.35% |
| Fayez Sarofim & Co.as of 31 Mar 2025 | 11.21m | 0.33% |
| Folketrygdfondetas of 31 Mar 2025 | 9.52m | 0.28% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 9.51m | 0.28% |
| Managed Account Advisors LLCas of 31 Mar 2025 | 8.61m | 0.25% |
| Renaissance Technologies LLCas of 31 Mar 2025 | 6.82m | 0.20% |
| ClearBridge Investments LLCas of 31 Mar 2025 | 6.63m | 0.20% |
| Everett Harris & Co.as of 31 Mar 2025 | 6.41m | 0.19% |
